Immuneering Corp (IMRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of IMRX. The 7-day demo opens the 1M and 3M ranges and puts IMRX on your watchlist.
Start 7-day demoLatest IMRX insider trades
About Immuneering Corp (IMRX)
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
- CAMBRIDGE, MA
- 57
- 2021
- XNAS
IMRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 650,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
IMRX insider transactions (Form 4)
735 Form 4 filings on record, the earliest from Jun 13, 2025, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Brett Matthew Hall - Officer | Grant or award | Class A Common Stock | 14,880 | $1.43 | $21K | |
| Diana Hausman - Director | Open-market purchase | Class A Common Stock | 2,500 | $3.60 | $9K | |
| Diana Hausman - Director | Open-market purchase | Class A Common Stock | 3,000 | $3.62 | $11K | |
| Benjamin J. Zeskind - Officer | Open-market purchase | Class A Common Stock | 2,985 | $3.38 | $10K | |
| Benjamin J. Zeskind - Officer | Open-market purchase | Class A Common Stock | 7,015 | $3.53 | $25K | |
 Leah R. Neufeld - Officer | Open-market purchase | Class A Common Stock | 700 | $3.57 | $2K | |
| Robert J. Carpenter - Director | Grant or award | Stock Option | 33,350 | $0.00 | - |
IMRX insider trading FAQ
What is the latest insider trade for IMRX?
Immuneering Corp (IMRX) had 1 insider filing in the last 90 days, with the most recent on 2026-07-17. The full record for IMRX runs to 35 Form 4 filings, the earliest from 2025-06-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying IMRX stock?
No insider purchases of IMRX were filed in the last 90 days. 18 purchases are on record for this company.
How many insiders are selling IMRX stock?
No insider sales of IMRX were filed in the last 90 days.
Where can I see IMRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects IMRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Andrew Gengos view on EDGAR
- - Benjamin J. Zeskind view on EDGAR
- - Brett Matthew Hall view on EDGAR
- - Thomas J. Schall view on EDGAR
- - Diana Hausman view on EDGAR
- - Robert J. Carpenter view on EDGAR
- - Laurie Keating view on EDGAR
- - Peter Feinberg view on EDGAR
- - Leah R. Neufeld view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where IMRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow IMRX with a 7-day demo
- IMRX on your watchlist
- Every IMRX Form 4 filing on record
- Up to 3 months of IMRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
